Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sally M Hunter

Showing results (1-10 of 21) with videos related to

Pageof 3
Sort By:
Journal of Clinical Pathology|February 26, 2015
Low-grade fibromatosis-like spindle cell carcinomas of the breast are molecularly exiguousElena A Takano, Sally M Hunter, Ian G Campbell, et al.
The American Journal of Pathology|April 15, 2014
Genomic aberrations of BRCA1-mutated fallopian tube carcinomasSally M Hunter, Georgina L Ryland, Phillip Moss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2012
Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrationsSally M Hunter, Kylie L Gorringe, Michael Christie, et al.
Pathology|October 9, 2025
Landscape of TP53 abnormalities and IGHV mutational profile in untreated Australian patients with chronic lymphocytic leukaemiaSally M Hunter, Lana Radulovic, Ella R Thompson, et al.
BMC Genomics|August 30, 2014
Inferring copy number and genotype in tumour exome dataKaushalya C Amarasinghe, Jason Li, Sally M Hunter, et al.
Genome Medicine|October 1, 2013
A simple consensus approach improves somatic mutation prediction accuracyDavid L Goode, Sally M Hunter, Maria A Doyle, et al.
Urologic Oncology|November 21, 2015
Searching for candidate genes in familial BRCAX mutation carriers with prostate cancerSally M Hunter, Simone M Rowley, David Clouston, et al.
BMC Research Notes|July 24, 2020
Molecular comparison of pure ovarian fibroma with serous benign ovarian tumoursSally M Hunter, Genevieve V Dall, Maria A Doyle, et al.
The Journal of Pathology|October 26, 2012
RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovaryGeorgina L Ryland, Sally M Hunter, Maria A Doyle, et al.
Hemasphere|June 9, 2026
Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE studyChan Y Cheah, Piers Blombery, Amanda Johnston, et al.
Pageof 3

Showing results (1-10 of 21) with videos related to

Sort By:
Pageof 3
Journal of Clinical Pathology|February 26, 2015
Low-grade fibromatosis-like spindle cell carcinomas of the breast are molecularly exiguousElena A Takano, Sally M Hunter, Ian G Campbell, et al.
The American Journal of Pathology|April 15, 2014
Genomic aberrations of BRCA1-mutated fallopian tube carcinomasSally M Hunter, Georgina L Ryland, Phillip Moss, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 15, 2012
Pre-invasive ovarian mucinous tumors are characterized by CDKN2A and RAS pathway aberrationsSally M Hunter, Kylie L Gorringe, Michael Christie, et al.
Pathology|October 9, 2025
Landscape of TP53 abnormalities and IGHV mutational profile in untreated Australian patients with chronic lymphocytic leukaemiaSally M Hunter, Lana Radulovic, Ella R Thompson, et al.
BMC Genomics|August 30, 2014
Inferring copy number and genotype in tumour exome dataKaushalya C Amarasinghe, Jason Li, Sally M Hunter, et al.
Genome Medicine|October 1, 2013
A simple consensus approach improves somatic mutation prediction accuracyDavid L Goode, Sally M Hunter, Maria A Doyle, et al.
Urologic Oncology|November 21, 2015
Searching for candidate genes in familial BRCAX mutation carriers with prostate cancerSally M Hunter, Simone M Rowley, David Clouston, et al.
BMC Research Notes|July 24, 2020
Molecular comparison of pure ovarian fibroma with serous benign ovarian tumoursSally M Hunter, Genevieve V Dall, Maria A Doyle, et al.
The Journal of Pathology|October 26, 2012
RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovaryGeorgina L Ryland, Sally M Hunter, Maria A Doyle, et al.
Hemasphere|June 9, 2026
Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE studyChan Y Cheah, Piers Blombery, Amanda Johnston, et al.
Pageof 3